ArticleBiomolecules & biomedicine2025
Tubular functional capacity and maladaptive parathyroid hormone response in early-stage chronic kidney disease.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical data regarding the interaction between tubular functional capacity (TFC) and maladaptive parathyroid gland response in early-stage chronic kidney disease (CKD) are limited. This study aimed to evaluate the association between parathyroid gland response, measured as intact parathyroid hormone (iPTH) serum concentration (pg/mL) using chemiluminescent microparticle immunoassay, and the dissociation between the decline in glomerular filtration rate (GFR) and TFC, assessed through radionuclide clearances. TFC was evaluated by measuring effective renal plasma flow (mERPF, ml/min/1.73m²) using (131I) Hippurate (131I-H) clearance, while GFR was measured using (99m) Tc-DTPA (mGFR, ml/min/1.73m²). Consecutive participants with preexisting CKD (N=111, female 44%, male 56%) were enrolled and stratified into four groups based on CKD stages (1, 2, 3a, and 3b). Median serum iPTH concentrations significantly differed between Stage 1 [23 (20.4-25.5) pg/mL] and Stage 2 [23.6 (20.5-26.8) pg/mL] compared to Stage 3a [38.1 (34.1-41.9) pg/mL] and Stage 3b [45.8 (39.7-51.9) pg/mL] (p=0.01). In Stage 1, there was a significant positive association between iPTH and mERPF (p=0.003). Conversely, in Stage 3b, iPTH was significantly negatively associated with both mGFR and mERPF (p<0.05 for both). Regression models that included the interaction between CKD stage and either mGFR or mERPF, alongside other predictors (age, CKD stage, body mass index, ionized calcium, and 25-hydroxyvitamin D), revealed significant associations with iPTH (p<0.05 for all variables). The assessment of TFC using 131I-H plasma clearance does not enhance the detection of maladaptive parathyroid gland responses compared to evaluating CKD stage and its relationship with declining glomerular and tubular clearances in early-stage CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.